Florida H353: Sickle Cell Disease Treatment of Pain Continuing Education

What the bill says

An act relating to sickle cell disease treatment of pain continuing education; amending s. 456.0301, F.S.; revising requirements for a continuing education course on prescribing controlled substances; providing an effective date.

From the introduced text, February 11, 2026:

An act relating to sickle cell disease treatment of pain continuing education; amending s. 456.0301, F.S.; revising requirements for a continuing education course on prescribing controlled substances; providing an effective date. Be It Enacted by the Legislature of the State of Florida: Section 1. Paragraph (a) of subsection (1) of section 456.0301, Florida Statutes, is amended to read: 456.0301 Requirement for instruction on controlled substance prescribing.— (1)(a) The appropriate board shall require each person registered with the United States Drug Enforcement Administration and authorized to prescribe controlled substances pursuant to 21 U.S.C. s. 822 to complete a board-approved 2-hour continuing education course on prescribing controlled substances offered by a statewide professional association of physicians in this state that is accredited to provide educational activities designated for the American Medical Association Physician's Recognition Award Category 1 Credit or the American Osteopathic Category 1-A continuing medical education credit as part of biennial license renewal. The course must include information on the current standards for prescribing controlled substances, CS/HB 353 2026 CODING: Words stricken are deletions; words underlined are additions. hb353-01-c1 Page 2 of FLORIDAHOUSEOFREPRESENTATIVES particularly opiates; alternatives to these standards; nonpharmacological therapies; prescribing emergency opioid antagonists; and the risks of opioid addiction following all stages of treatment in the management of acute pain; and the treatment of pain for patients with sickle …

Read the full official text

Sponsors

• Robinson, Felicia (D, HD-104) · primary sponsor
• Bartleman, Robin (D, HD-103)
• Campbell, Daryl (D, HD-099)
• Hunschofsky, Christine (D, HD-095)
• Maney, Patt (R, HD-004)
• Maney (R, 4)

Latest actions

1. March 11, 2026: Laid on Table; Companion bill(s) passed, see CS/SB 844 (Ch. 2026-6)
2. February 25, 2026: Added to Second Reading Calendar
3. February 25, 2026: Bill released to House Calendar
4. February 25, 2026: Reported out of Health & Human Services Committee
5. February 24, 2026: Favorable by Health & Human Services Committee
6. February 20, 2026: Added to Health & Human Services Committee agenda
7. February 12, 2026: Now in Health & Human Services Committee
8. February 12, 2026: Referred to Health & Human Services Committee
9. February 11, 2026: 1st Reading (Committee Substitute 1)
10. February 11, 2026: CS Filed

Votes

• House: Health & Human Services Committee (February 24, 2026): 23 yea, 0 nay, passed
• House: Health & Human Services Committee (February 24, 2026): 23 yea, 0 nay, passed
• House: Health Professions & Programs Subcommittee (February 11, 2026): 15 yea, 0 nay, passed
• House: Health Professions & Programs Subcommittee (February 11, 2026): 15 yea, 0 nay, passed

Common questions

What is H353?

H353 is a bill in the Florida Legislature (2026 Regular Session): Sickle Cell Disease Treatment of Pain Continuing Education.

What does H353 do?

In its own words: An act relating to sickle cell disease treatment of pain continuing education; amending s. 456.0301, F.S.; revising requirements for a continuing education course on prescribing controlled substances; providing an effective date.

What is the status of H353?

Passed one chamber as of March 11, 2026. Latest action: Laid on Table; Companion bill(s) passed, see CS/SB 844 (Ch. 2026-6) (March 11, 2026).

Who sponsored H353?

Robinson, Felicia (D, HD-104), with 5 co-sponsors.

Where is the official record for H353?

On the Florida Legislature website: https://www.flsenate.gov/Session/Bill/2026/353